Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Rheumatology

• Publication date

  2003-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/RHEUMATOLOGY/KEG205PMID 12730532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alendronate

  2012cited by this paper
• Active vitamin D metabolites in glucocorticoid-induced osteoporosis

  2009cited by this paper
• Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats

  2007cited by this paper
• The effect on bone mass and bone markers of different doses of ibandronate — A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study

  2006cited by this paper
• The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by45ca kinetics in the intact rat

  2005cited by this paper
• the Effect of

  2004cited by this paper
• Treatment of postmenopausal osteoporosis.

  2002cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

  2001cited by this paper
• Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis

  2001cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis

  2001cited by this paper
• Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study

  2000cited by this paper
• Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial

  2000cited by this paper
• Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.

  2000cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management

  2000cited by this paper
• Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

  2000cited by this paper
• Is enough attention being given to the adverse effects of corticosteroid therapy?

  2000cited by this paper
• Serum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective Study

  2000cited by this paper
• The Use of Biochemical Markers of Bone Turnover in Osteoporosis

  2000cited by this paper
• A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.

  2000cited by this paper
• Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study

  1999cited by this paper
• Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.

  1999cited by this paper
• Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  1999cited by this paper
• Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

  1999cited by this paper
• [Esophagitis associated with the use of alendronate].

  1999cited by this paper
• Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

  1998cited by this paper
• Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

  1998cited by this paper
• Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

  1998cited by this paper
• Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.

  1997cited by this paper
• Glucocorticoid osteoporosis--mechanisms and management.

  1997cited by this paper
• Ibandronate in oncology

  1997cited by this paper
• Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.

  1997cited by this paper
• Bisphosphonates in the treatment of osteoporosis.

  1997cited by this paper
• Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

  1997cited by this paper
• The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study

  1996cited by this paper
• Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study

  1996cited by this paper
• Esophagitis associated with the use of alendronate.

  1996cited by this paper
• American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

  1996cited by this paper
• Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

  1996cited by this paper
• Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.

  1996cited by this paper
• Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study

  1996cited by this paper
• Adverse Effects of Bisphosphonates

  1996cited by this paper
• Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

  1996cited by this paper
• Multiple dose regimens. Impact on compliance.

  1995cited by this paper
• Rheumatoid arthritis, corticosteroid therapy and hip fracture.

  1995cited by this paper
• Effects of continuous and cyclical administration of ibandronate on bone mass in ovariectomized (OVX) aged rats

  1995cited by this paper
• Polypharmacy in the Aged

  1994cited by this paper
• Pamidronate: An unrecognized problem in gastrointestinal tolerability

  1994cited by this paper
• A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

  1993cited by this paper
• Corticosteroid-induced osteoporosis.

  1993cited by this paper
• Polypharmacy

  1993cited by this paper
• Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.

  1992cited by this paper
• Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.

  1991cited by this paper
• Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

  1991cited by this paper
• Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.

  1991cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management.

  1990cited by this paper
• Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group.

  1990cited by this paper
• Appendicular Bone Density and Age Predict Hip Fracture in Women

  1990cited by this paper
• Corticosteroid effects on proximal femur bone loss

  1990cited by this paper
• Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.

  1986cited by this paper
• Patterns of drug taking in patients with chronic airflow obstruction.

  1985cited by this paper
• Steroid-induced fractures and bone loss in patients with asthma.

  1983cited by this paper
• Croup: pathogenesis and management.

  1983cited by this paper
• Glucocorticoid-induced osteoporosis.

  1983cited by this paper
• Misuse of Prescription Medications by Outpatients

  1969cited by this paper
• To be taken as directed.

  1968cited by this paper
• Drugs

  1967cited by this paper

• Risk for osteoporosis and fracture with glucocorticoids.

  2022cites this paper
• Glucocorticoid-induced osteoporosis and Cushing’s syndrome

  2021cites this paper
• Orthoses for Osteoporosis

  2019cites this paper
• Adjuvant drug-assisted bone healing: Part III – Further strategies for local and systemic modulation

  2019cites this paper
• Importancia de los niveles de vitamina d en la prevención secundaria de la osteoporosis corticoidea

  2017cites this paper
• Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.

  2017cites this paper
• Prevention and Treatment of Bone Disease in Systemic Lupus Erythematosus

  2016cites this paper
• Glucocorticoid-induced Osteoporosis.

  2016cites this paper
• Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis

  2016cites this paper
• Fracture pain-Traveling unknown pathways.

  2016cites this paper
• MALE OSTEOPOROSIS

  2015cites this paper
• Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis

  2015cites this paper
• Systemic lupus erythematosus, bone health, and osteoporosis

  2015cites this paper
• Bone safety of low‐dose glucocorticoids in rheumatic diseases

  2014cites this paper
• Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

  2014cites this paper
• Review of New Guidelines for the Management of Glucocorticoid Induced Osteoporosis

  2013cites this paper
• Chapter 49 – Glucocorticoid-Induced Osteoporosis

  2013cites this paper
• Osteoporosis inducida por glucocorticoides

  2012cites this paper
• Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.

  2012cites this paper
• Indian rheumatology association guidelines for management of glucocorticoid-induced osteoporosis Endorsed by: Endocrine Society of India and Indian Society for Bone & Mineral Research

  2011cites this paper
• Glucocorticoid-Induced Osteoporosis: A Review

  2010cites this paper
• Prevention and treatment of systemic glucocorticoid side effects

  2010cites this paper
• Treatment of osteoporosis after liver transplantation with ibandronate

  2010cites this paper
• Effekte des Bisphosphonats Ibandronat auf Knochendichte und Nierenfunktion bei Patienten nach allogener Nierentransplantation

  2009cites this paper
• Osteoporosis and Drugs

  2009cites this paper
• Osteoporosis secundaria a fármacos

  2009cites this paper
• Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance

  2009cites this paper
• New and emerging treatments for osteoporosis

  2009cites this paper
• Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids.

  2009cites this paper
• Grundlagen und Management der glukokortikoidinduzierten Osteoporose

  2008cites this paper
• [Basics and management of glucocorticoid-induced osteoporosis].

  2008cites this paper
• [Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].

  2008cites this paper
• CHAPTER 44 – Glucocorticoid-Induced Osteoporosis

  2008cites this paper
• Treatment of glucocorticoid-induced osteoporosis with active vitamin D_3 analogues

  2008cites this paper
• Calcaneus BMD short-term precision in young and elderly subjects using the DXL Calscan.

  2008cites this paper
• Интермиттирующая терапия остеопороза с помощью внутривенной формыибандроната

  2008cites this paper
• Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna

  2008cites this paper
• Secondary osteoporosis during long-term steroid treatment

  2007cites this paper
• A systematic review of measures used to assess chronic musculoskeletal pain in clinical and randomized controlled clinical trials.

  2007cites this paper
• Diagnosis and treatment of giant cell arteritis

  2007cites this paper
• Optimal Timing of a Single Dose of Zoledronic Acid to Increase Strength in Rat Fracture Repair

  2007cites this paper
• Prevention and treatment of glucocorticoid-induced osteoporosis

  2007cites this paper
• A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.

  2007cites this paper
• Corticotrophins, Corticosteroids and Prostaglandins

  2007cites this paper
• Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis

  2007cites this paper
• Ibandronate, an Experimental Intravenous Bisphosphonate for Osteoporosis, Bone Metastases, and Hypercalcemia of Malignancy

  2006cites this paper
• Giant Cell Arteritis and Polymyalgia Rheumatica

  2006cites this paper
• Glucocorticoid-induced osteoporosis.

  2006cites this paper
• Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.

  2006cites this paper
• The DXL Calscan heel densitometer: evaluation and diagnostic thresholds.

  2006cites this paper
• Ibandronate Intravenous

  2006cites this paper
• review article Glucocorticoid-Induced Osteoporosis

  2006cites this paper
• Calscan heel densitometer : evaluation and diagnostic thresholds

  2006cites this paper
• Acute renal effects of intravenous bisphosphonates in the rat.

  2005cites this paper
• Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.

  2005cites this paper
• RevisiónBisfosfonatos intravenososIntravenous bisphosphonates

  2005cites this paper
• [Intravenous bisphosphonates].

  2005cites this paper
• Diskussiya: VOZMOZhNOSTI I OShIBKI NEINVAZIVNOY KOLIChESTVENNOY OTsENKI MASSY KOSTNOY TKANI DLYa DIAGNOSTIKI OSTEOPOROZARetsenzii na stat'yu A.V. Smirnova i T.O. Chernovoy

  2005cites this paper
• The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation

  2005cites this paper
• High bone-binding capacity of ibandronate in hemodialysis patients.

  2005cites this paper
• Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.

  2005cites this paper
• Bisphosphonates for osteoporosis prevention and treatment

  2005cites this paper
• Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update

  2004cites this paper
• Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing

  2004cites this paper
• Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

  2004cites this paper
• Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease

  2004cites this paper
• Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies

  2004influential citation
• IBANDRONATE: A POTENT NEW BISPHOSPHONATE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS

  2003cites this paper
• Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

  2003cites this paper
• [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].

  2003cites this paper
• Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

  2003cites this paper
• American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

  1996cites this paper